|
|
Blood, 1 October 2005, Vol. 106, No. 7, pp. 2276-2279.
Prepublished online as a Blood First Edition Paper on June 16, 2005; DOI 10.1182/blood-2005-05-1858.
 Previous Article | Table of Contents | Next Article 
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma
Grzegorz S. Nowakowski,
Thomas E. Witzig,
David Dingli,
Michal J. Tracz,
Morie A. Gertz,
Martha Q. Lacy,
John A. Lust,
Angela Dispenzieri,
Philip R. Greipp,
Robert A. Kyle, and
S. Vincent Rajkumar
From the Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN.
We detected circulating plasma cells (PCs) by flow cytometry in 302 patients with newly diagnosed multiple myeloma (MM) by gating on CD38+CD45- cells. The number of circulating PCs per 50 000 mononuclear cells was reported. In 80 (27%) patients, no circulating PC were seen; 106 (35%) patients had 1 to 10 and 115 (38%) patients had more than 10 circulating PCs. Median overall survival for the 302 patients was 47 months. Patients with 10 or fewer circulating PCs had a median survival of 58.7 months, whereas patients with more than 10 circulating PCs had a median survival of 37.3 months (P = .001). On multivariate analysis, the prognostic value of circulating PCs was independent of  2-microglobulin, albumin, and C-reactive protein. There was only a weak correlation between tumor mass and circulating PCs, suggesting that the appearance of circulating PCs may be a reflection of tumor biology. We conclude that the number of circulating PCs measured by flow cytometry in patients with newly diagnosed MM is an independent predictor of survival.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
B. Paiva, M.-B. Vidriales, G. Mateo, J. J. Perez, M. A. Montalban, A. Sureda, L. Montejano, N. C. Gutierrez, A. Garcia de Coca, N. de las Heras, et al.
The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients
Blood,
November 12, 2009;
114(20):
4369 - 4372.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Azab, F. Azab, S. Blotta, C. M. Pitsillides, B. Thompson, J. M. Runnels, A. M. Roccaro, H. T. Ngo, M. R. Melhem, A. Sacco, et al.
RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma
Blood,
July 16, 2009;
114(3):
619 - 629.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. E. Craig and K. A. Foon
Flow cytometric immunophenotyping for hematologic neoplasms
Blood,
April 15, 2008;
111(8):
3941 - 3967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Rawstron, A. Orfao, M. Beksac, L. Bezdickova, R. A. Brooimans, H. Bumbea, K. Dalva, G. Fuhler, J. Gratama, D. Hose, et al.
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
Haematologica,
March 1, 2008;
93(3):
431 - 438.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Alsayed, H. Ngo, J. Runnels, X. Leleu, U. K. Singha, C. M. Pitsillides, J. A. Spencer, T. Kimlinger, J. M. Ghobrial, X. Jia, et al.
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma
Blood,
April 1, 2007;
109(7):
2708 - 2717.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Dingli, G. S. Nowakowski, A. Dispenzieri, M. Q. Lacy, S. R. Hayman, S. V. Rajkumar, P. R. Greipp, M. R. Litzow, D. A. Gastineau, T. E. Witzig, et al.
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system
Blood,
April 15, 2006;
107(8):
3384 - 3388.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Z. Orlowski
Initial Therapy of Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation
Hematology,
January 1, 2006;
2006(1):
338 - 347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
